Profiling amyloid-β peptides as biomarkers for cerebral amyloid angiopathy.
Alzheimer's disease
amyloid-β
biomarkers
cerebral amyloid angiopathy
cerebrospinal fluid
mass spectrometry
Journal
Journal of neurochemistry
ISSN: 1471-4159
Titre abrégé: J Neurochem
Pays: England
ID NLM: 2985190R
Informations de publication
Date de publication:
16 Feb 2024
16 Feb 2024
Historique:
revised:
08
01
2024
received:
25
10
2023
accepted:
24
01
2024
medline:
16
2
2024
pubmed:
16
2
2024
entrez:
16
2
2024
Statut:
aheadofprint
Résumé
Brain amyloid-β (Aβ) deposits are key pathological hallmarks of both cerebral amyloid angiopathy (CAA) and Alzheimer's disease (AD). Microvascular deposits in CAA mainly consist of the Aβ
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIH HHS
ID : 5R01NS104147-02
Pays : United States
Organisme : ZonMw
ID : 733050822
Pays : Netherlands
Informations de copyright
© 2024 The Authors. Journal of Neurochemistry published by John Wiley & Sons Ltd on behalf of International Society for Neurochemistry.
Références
Banerjee, G., Ambler, G., Keshavan, A., Paterson, R. W., Foiani, M. S., Toombs, J., Heslegrave, A., Dickson, J. C., Fraioli, F., Groves, A. M., Lunn, M. P., Fox, N. C., Zetterberg, H., Schott, J. M., & Werring, D. J. (2020). Cerebrospinal fluid biomarkers in cerebral amyloid angiopathy. Journal of Alzheimer's Disease, 74, 1189-1201.
Brinkmalm, G., Hong, W., Wang, Z., Liu, W., O'Malley, T. T., Sun, X., Frosch, M. P., Selkoe, D. J., Portelius, E., Zetterberg, H., Blennow, K., & Walsh, D. M. (2019). Identification of neurotoxic cross-linked amyloid-β dimers in the Alzheimer's brain. Brain, 142, 1441-1457.
Cabrera, E., Mathews, P., Mezhericher, E., Beach, T. G., Deng, J., Neubert, T. A., Rostagno, A., & Ghiso, J. (2018). Aβ truncated species: Implications for brain clearance mechanisms and amyloid plaque deposition. Biochimica et Biophysica Acta - Molecular Basis of Disease, 1864, 208-225.
Charidimou, A., & Boulouis, G. (2022). Clinical diagnosis of probable cerebral amyloid angiopathy: Diagnostic accuracy meta-analysis of the Boston criteria. Stroke, 53, 3679-3687.
Charidimou, A., Boulouis, G., Frosch, M. P., Baron, J. C., Pasi, M., Albucher, J. F., Banerjee, G., Barbato, C., Bonneville, F., Brandner, S., Calviere, L., Caparros, F., Casolla, B., Cordonnier, C., Delisle, M. B., Deramecourt, V., Dichgans, M., Gokcal, E., Herms, J., … Greenberg, S. M. (2022). The Boston criteria version 2.0 for cerebral amyloid angiopathy: A multicentre, retrospective, MRI-neuropathology diagnostic accuracy study. Lancet Neurology, 21, 714-725.
Charidimou, A., Boulouis, G., Gurol, M. E., Ayata, C., Bacskai, B. J., Frosch, M. P., Viswanathan, A., & Greenberg, S. M. (2017). Emerging concepts in sporadic cerebral amyloid angiopathy. Brain, 140, 1829-1850.
Das, A. S., Gokcal, E., Regenhardt, R. W., Horn, M. J., Schwab, K., Daoud, N., Viswanathan, A., Kimberly, W. T., Goldstein, J. N., Biffi, A., Rost, N., Rosand, J., Schwamm, L. H., Greenberg, S. M., & Gurol, M. E. (2023). Improving detection of cerebral small vessel disease aetiology in patients with isolated lobar intracerebral haemorrhage. Stroke and Vascular Neurology, 8, 26-33.
De Kort, A. M., Kuiperij, H. B., Marques, T. M., Jäkel, L., van den Berg, E., Kersten, I., van Berckel-Smit, H. E. P., Duering, M., Stoops, E., Abdo, W. F., Rasing, I., Voigt, S., Koemans, E. A., Kaushik, K., Warren, A. D., Greenberg, S. M., Brinkmalm, G., Terwindt, G. M., Wermer, M. J. H., … Verbeek, M. M. (2023). Decreased cerebrospinal fluid amyloid β 38, 40, 42, and 43 levels in sporadic and hereditary cerebral amyloid angiopathy. Annals of Neurology, 93, 1173-1186.
DeSimone, C. V., Graff-Radford, J., El-Harasis, M. A., Rabinstein, A. A., Asirvatham, S. J., & Holmes, D. R., Jr. (2017). Cerebral amyloid angiopathy: Diagnosis, clinical implications, and management strategies in atrial fibrillation. Journal of the American College of Cardiology, 70, 1173-1182.
Dong, M., Paul, T. J., Hoffmann, Z., Chan, K., Hu, D., Ai, H., & Prabhakar, R. (2016). Structural and material properties of amyloid Aβ40/42 fibrils. ChemPhysChem, 17, 2558-2566.
Dunys, J., Valverde, A., & Checler, F. (2018). Are N- and C-terminally truncated Aβ species key pathological triggers in Alzheimer's disease? The Journal of Biological Chemistry, 293, 15419-15428.
Faul, F., Erdfelder, E., Lang, A. G., & Buchner, A. (2007). G*power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behavior Research Methods, 39, 175-191.
Gkanatsiou, E., Portelius, E., Toomey, C. E., Blennow, K., Zetterberg, H., Lashley, T., & Brinkmalm, G. (2019). A distinct brain beta amyloid signature in cerebral amyloid angiopathy compared to Alzheimer's disease. Neuroscience Letters, 701, 125-131.
Grangeon, L., Paquet, C., Guey, S., Zarea, A., Martinaud, O., Rotharmel, M., Maltête, D., Quillard-Muraine, M., Nicolas, G., Charbonnier, C., Chabriat, H., & Wallon, D. (2022). Cerebrospinal fluid profile of tau, phosphorylated tau, Aβ42, and Aβ40 in probable cerebral amyloid angiopathy. Journal of Alzheimer's Disease, 87, 791-802.
Greenberg, S. M., Bacskai, B. J., Hernandez-Guillamon, M., Pruzin, J., Sperling, R., & van Veluw, S. J. (2020). Cerebral amyloid angiopathy and Alzheimer disease-One peptide, two pathways. Nature Reviews. Neurology, 16, 30-42.
Haass, C., Kaether, C., Thinakaran, G., & Sisodia, S. (2012). Trafficking and proteolytic processing of APP. Cold Spring Harbor Perspectives in Medicine, 2, a006270.
Jack, C. R., Jr., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., Liu, E., Molinuevo, J. L., Montine, T., Phelps, C., Rankin, K. P., Rowe, C. C., Scheltens, P., Siemers, E., Snyder, H. M., & Sperling, R. (2018). NIA-AA research framework: Toward a biological definition of Alzheimer's disease. Alzheimers Dement, 14, 535-562.
Jäkel, L., De Kort, A. M., Klijn, C. J. M., Schreuder, F., & Verbeek, M. M. (2022). Prevalence of cerebral amyloid angiopathy: A systematic review and meta-analysis. Alzheimers Dement, 18, 10-28.
Janelidze, S., Zetterberg, H., Mattsson, N., Palmqvist, S., Vanderstichele, H., Lindberg, O., van Westen, D., Stomrud, E., Minthon, L., Blennow, K., & Hansson, O. (2016). CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios: Better diagnostic markers of Alzheimer disease. Annals of Clinical Translational Neurology, 3, 154-165.
Jarrett, J. T., Berger, E. P., & Lansbury, P. T., Jr. (1993). The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: Implications for the pathogenesis of Alzheimer's disease. Biochemistry, 32, 4693-4697.
Kakuda, N., Miyasaka, T., Iwasaki, N., Nirasawa, T., Wada-Kakuda, S., Takahashi-Fujigasaki, J., Murayama, S., Ihara, Y., & Ikegawa, M. (2017). Distinct deposition of amyloid-β species in brains with Alzheimer's disease pathology visualized with MALDI imaging mass spectrometry. Acta Neuropathologica Communications, 5, 73.
Kirabali, T., Rigotti, S., Siccoli, A., Liebsch, F., Shobo, A., Hock, C., Nitsch, R. M., Multhaup, G., & Kulic, L. (2019). The amyloid-β degradation intermediate Aβ34 is pericyte-associated and reduced in brain capillaries of patients with Alzheimer's disease. Acta Neuropathologica Communications, 7, 194.
Leinenbach, A., Pannee, J., Dülffer, T., Huber, A., Bittner, T., Andreasson, U., Gobom, J., Zetterberg, H., Kobold, U., Portelius, E., & Blennow, K. (2014). Mass spectrometry-based candidate reference measurement procedure for quantification of amyloid-β in cerebrospinal fluid. Clinical Chemistry, 60, 987-994.
Lewczuk, P., Matzen, A., Blennow, K., Parnetti, L., Molinuevo, J. L., Eusebi, P., Kornhuber, J., Morris, J. C., & Fagan, A. M. (2017). Cerebrospinal fluid Aβ42/40 corresponds better than Aβ42 to amyloid PET in Alzheimer's disease. Journal of Alzheimer's Disease, 55, 813-822.
Linn, J., Halpin, A., Demaerel, P., Ruhland, J., Giese, A. D., Dichgans, M., van Buchem, M. A., Bruckmann, H., & Greenberg, S. M. (2010). Prevalence of superficial siderosis in patients with cerebral amyloid angiopathy. Neurology, 74, 1346-1350.
Margraf, N. G., Jensen-Kondering, U., Weiler, C., Leypoldt, F., Maetzler, W., Philippen, S., Bartsch, T., Flüh, C., Röcken, C., Möller, B., Royl, G., Neumann, A., Brüggemann, N., Roeben, B., Schulte, C., Bender, B., Berg, D., & Kuhlenbäumer, G. (2022). Cerebrospinal fluid biomarkers in cerebral amyloid angiopathy: New data and quantitative meta-analysis. Frontiers in Aging Neuroscience, 14, 783996.
McIntee, F. L., Giannoni, P., Blais, S., Sommer, G., Neubert, T. A., Rostagno, A., & Ghiso, J. (2016). In vivo differential brain clearance and catabolism of monomeric and oligomeric Alzheimer's Aβ protein. Frontiers in Aging Neuroscience, 8, 223.
Moro, M. L., Giaccone, G., Lombardi, R., Indaco, A., Uggetti, A., Morbin, M., Saccucci, S., Di Fede, G., Catania, M., Walsh, D. M., Demarchi, A., Rozemuller, A., Bogdanovic, N., Bugiani, O., Ghetti, B., & Tagliavini, F. (2012). APP mutations in the Aβ coding region are associated with abundant cerebral deposition of Aβ38. Acta Neuropathologica, 124, 809-821.
Motter, R., Vigo-Pelfrey, C., Kholodenko, D., Barbour, R., Johnson-Wood, K., Galasko, D., Chang, L., Miller, B., Clark, C., Green, R., Olson, D., Southwick, P., Wolfert, R., Munroe, B., Lieberburg, I., Seubert, P., & Schenk, D. (1995). Reduction of β-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease. Annals of Neurology, 38, 643-648.
Nasreddine, Z. S., Phillips, N. A., Bédirian, V., Charbonneau, S., Whitehead, V., Collin, I., Cummings, J. L., & Chertkow, H. (2005). The Montreal cognitive assessment, MoCA: A brief screening tool for mild cognitive impairment. Journal of the American Geriatrics Society, 53, 695-699.
Pannee, J., Portelius, E., Minthon, L., Gobom, J., Andreasson, U., Zetterberg, H., Hansson, O., & Blennow, K. (2016). Reference measurement procedure for CSF amyloid beta (Aβ)(1-42) and the CSF Aβ(1-42) /Aβ(1-40) ratio-A cross-validation study against amyloid PET. Journal of Neurochemistry, 139, 651-658.
Qi, X. M., & Ma, J. F. (2017). The role of amyloid beta clearance in cerebral amyloid angiopathy: More potential therapeutic targets. Translational Neurodegeneration, 6, 22.
Reinert, J., Martens, H., Huettenrauch, M., Kolbow, T., Lannfelt, L., Ingelsson, M., Paetau, A., Verkkoniemi-Ahola, A., Bayer, T. A., & Wirths, O. (2014). Aβ38 in the brains of patients with sporadic and familial Alzheimer's disease and transgenic mouse models. Journal of Alzheimer's Disease, 39, 871-881.
Reinert, J., Richard, B. C., Klafki, H. W., Friedrich, B., Bayer, T. A., Wiltfang, J., Kovacs, G. G., Ingelsson, M., Lannfelt, L., Paetau, A., Bergquist, J., & Wirths, O. (2016). Deposition of C-terminally truncated Aβ species Aβ37 and Aβ39 in Alzheimer's disease and transgenic mouse models. Acta Neuropathologica Communications, 4, 24.
Sveikata, L., Charidimou, A., & Viswanathan, A. (2022). Vessels sing their ARIAs: The role of vascular amyloid in the age of aducanumab. Stroke, 53, 298-302.
van Etten, E. S., Verbeek, M. M., van der Grond, J., Zielman, R., van Rooden, S., van Zwet, E. W., van Opstal, A. M., Haan, J., Greenberg, S. M., van Buchem, M. A., Wermer, M. J., & Terwindt, G. M. (2017). β-Amyloid in CSF: Biomarker for preclinical cerebral amyloid angiopathy. Neurology, 88, 169-176.
Verbeek, M. M., Kremer, B. P., Rikkert, M. O., Van Domburg, P. H., Skehan, M. E., & Greenberg, S. M. (2009). Cerebrospinal fluid amyloid β40 is decreased in cerebral amyloid angiopathy. Annals of Neurology, 66, 245-249.
Vos, S. J., Visser, P. J., Verhey, F., Aalten, P., Knol, D., Ramakers, I., Scheltens, P., Rikkert, M. G., Verbeek, M. M., & Teunissen, C. E. (2014). Variability of CSF Alzheimer's disease biomarkers: Implications for clinical practice. PLoS One, 9, e100784.
Weller, R. O., Massey, A., Newman, T. A., Hutchings, M., Kuo, Y. M., & Roher, A. E. (1998). Cerebral amyloid angiopathy: Amyloid beta accumulates in putative interstitial fluid drainage pathways in Alzheimer's disease. The American Journal of Pathology, 153, 725-733.